{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:08:52Z","timestamp":1790770132796,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:00:00Z","timestamp":1614729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:00:00Z","timestamp":1614729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1038\/s41409-020-01198-2","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T17:03:24Z","timestamp":1614791004000},"page":"1700-1709","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trial"],"prefix":"10.1038","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7600-3329","authenticated-orcid":false,"given":"Benoit","family":"Tessoulin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chiron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Oberic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Bouadballah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7651-9189","authenticated-orcid":false,"given":"Emmanuel","family":"Gyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4689-3882","authenticated-orcid":false,"given":"Gandhi","family":"Damaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Ribrag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9my","family":"Gressin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Feugier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Casasnovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hac\u00e8ne","family":"Zerazhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Lemonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Maisonneuve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clementine","family":"Joubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Van Den Neste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Tilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Le Gouill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,3]]},"reference":[{"key":"1198_CR1","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184\u201390.","journal-title":"J Clin Oncol."},{"key":"1198_CR2","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1182\/blood.V77.7.1587.1587","volume":"77","author":"T Philip","year":"1991","unstructured":"Philip T, Chauvin F, Armitage J, Bron D, Hagenbeek A, Biron P, et al. Parma international protocol: pilot study of DHAP followed by involved- field radiotherapy and BEAC with autologous bone marrow transplantation. Blood. 1991;77:1587\u201392.","journal-title":"Blood."},{"key":"1198_CR3","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1995;333:1540\u20135.","journal-title":"N Engl J Med."},{"key":"1198_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1182\/blood.V71.1.117.117","volume":"71","author":"WS Velasquez","year":"1988","unstructured":"Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988;71:117\u201322.","journal-title":"Blood."},{"key":"1198_CR5","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1200\/JCO.2003.11.126","volume":"21","author":"ML Rothenberg","year":"2003","unstructured":"Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol. 2003;21:2059\u201369.","journal-title":"J Clin Oncol."},{"key":"1198_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S1470-2045(15)00410-6","volume":"17","author":"S Hironaka","year":"2016","unstructured":"Hironaka S, Sugimoto N, Yamaguchi K, Moriwaki T, Komatsu Y, Nishina T, et al. S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17:99\u2013108.","journal-title":"Lancet Oncol."},{"key":"1198_CR7","doi-asserted-by":"crossref","unstructured":"Mehmood RK. Review of cisplatin and oxaliplatin in current immunogenic and monoclonal antibody treatments. Oncol Rev. 2014;8. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4419649\/.","DOI":"10.4081\/oncol.2014.256"},{"key":"1198_CR8","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00277-017-2981-2","volume":"96","author":"B Tessoulin","year":"2017","unstructured":"Tessoulin B, Thomare P, Delande E, Moynard J, Gastinne T, Moreau A, et al. Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+\/-R) is an effective treatment with low toxicity in Hodgkin\u2019s and non-Hodgkin\u2019s lymphomas. Ann Hematol. 2017;96:943\u201350.","journal-title":"Ann Hematol."},{"key":"1198_CR9","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/hon.2328","volume":"35","author":"F Tixier","year":"2017","unstructured":"Tixier F, Ranchon F, Iltis A, Vantard N, Schwiertz V, Bachy E, et al. Comparative toxicities of 3 platinum-containing chemotherapy regimens in relapsed\/refractory lymphoma patients. Hematol Oncol. 2017;35:584\u201390.","journal-title":"Hematol Oncol"},{"key":"1198_CR10","doi-asserted-by":"publisher","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv62\u201371.","journal-title":"Ann Oncol."},{"key":"1198_CR11","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"O Hermine","year":"2016","unstructured":"Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388:565\u201375.","journal-title":"Lancet."},{"key":"1198_CR12","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","volume":"377","author":"S Le Gouill","year":"2017","unstructured":"Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377:1250\u201360.","journal-title":"N Engl J Med."},{"key":"1198_CR13","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1038\/s41375-019-0463-3","volume":"33","author":"A Papin","year":"2019","unstructured":"Papin A, Tessoulin B, Bellanger C, Moreau A, Le Bris Y, Maisonneuve H, et al. CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages. Leukemia. 2019;33:2442\u201353.","journal-title":"Leukemia."},{"key":"1198_CR14","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3816\/CLML.2010.n.055","volume":"10","author":"J Lignon","year":"2010","unstructured":"Lignon J, Sibon D, Madelaine I, Brice P, Franchi P, Briere J, et al. Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed\/refractory B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2010;10:262\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"1198_CR15","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/S0006-2952(97)81490-6","volume":"52","author":"O Rixe","year":"1996","unstructured":"Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute\u2019s Anticancer Drug Screen panel. Biochem Pharmacol. 1996;52:1855\u201365.","journal-title":"Biochem Pharmacol."},{"key":"1198_CR16","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/bjh.14141","volume":"174","author":"A Obrador-Hevia","year":"2016","unstructured":"Obrador-Hevia A, Serra-Sitjar M, Rodr\u00edguez J, Belayachi L, Bento L, Garc\u00eda-Recio M, et al. Efficacy of the GemOx-R regimen leads to the identification of oxaliplatin as a highly effective drug against mantle cell lymphoma. Br J Haematol. 2016;174:899\u2013910.","journal-title":"Br J Haematol."},{"key":"1198_CR17","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.3109\/10428194.2013.825906","volume":"55","author":"A Laurell","year":"2014","unstructured":"Laurell A, Kolstad A, Jerkeman M, R\u00e4ty R, Geisler CH. High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group mantle cell lymphoma 5 trial. Leuk Lymphoma. 2014;55:1206\u20138.","journal-title":"Leuk Lymphoma."}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-01198-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-01198-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-01198-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:17:28Z","timestamp":1684617448000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01198-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,3]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1198"],"URL":"https:\/\/doi.org\/10.1038\/s41409-020-01198-2","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,3]]},"assertion":[{"value":"7 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The LyMa study was performed according to the Declaration of Helsinki and approved by an ethics committee (CPP Ouest 1\u201311 March, 2008), ClinicalTrials.gov (NCT00921414). Patients signed informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}